Associations - ALK fusion

ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval	brigatinib Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A2 - Guideline	lorlatinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK inhibitor Sensitive: A2 - Guideline	ALK inhibitor Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	ALK fusion ALK fusion	Melanoma Melanoma	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	ALK fusion ALK fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	brigatinib Sensitive: A2 - Guideline	brigatinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	ALK fusion ALK fusion	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: A2 - Guideline	alectinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: B - Late Trials	crizotinib Sensitive: B - Late Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: C2 – Inclusion Criteria	alectinib Sensitive: C2 – Inclusion Criteria
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	anlotinib Sensitive: C3 – Early Trials	anlotinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: C3 – Early Trials	ceritinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	ALK fusion ALK fusion	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	ceritinib Sensitive: C3 – Early Trials	ceritinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	pemetrexed Resistant: C3 – Early Trials	pemetrexed Resistant: C3 – Early Trials
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	bevacizumab + alectinib Sensitive: C3 – Early Trials	bevacizumab + alectinib Sensitive: C3 – Early Trials
ALK fusion ALK fusion	Lung Cancer Lung Cancer	ALK fusion ALK fusion	Lung Cancer Lung Cancer	crizotinib Resistant: C3 – Early Trials	crizotinib Resistant: C3 – Early Trials
ALK fusion ALK fusion	Lung Adenocarcinoma LUAD	ALK fusion ALK fusion	Lung Adenocarcinoma LUAD	crizotinib Sensitive: C4 – Case Studies	crizotinib Sensitive: C4 – Case Studies
ALK fusion ALK fusion	Glioma Glioma	ALK fusion ALK fusion	Glioma Glioma	lorlatinib Sensitive: C4 – Case Studies	lorlatinib Sensitive: C4 – Case Studies
ALK fusion ALK fusion	Triple Negative Breast Cancer Triple Negative Breast Cancer	ALK fusion ALK fusion	Triple Negative Breast Cancer Triple Negative Breast Cancer	crizotinib Sensitive: C4 – Case Studies	crizotinib Sensitive: C4 – Case Studies
ALK fusion ALK fusion	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	ALK fusion ALK fusion	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	gilteritinib Sensitive: D – Preclinical	gilteritinib Sensitive: D – Preclinical